Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692803 · ClinicalTrials.gov registry record
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
A clinical trial of Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,043
- Enrollment target
- 1
- Study location
NCT06692803 is a study of Chronic Myeloid Leukemia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,043 participants, above the 152-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (1244% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06692803, a study of Chronic Myeloid Leukemia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,043 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database. Adult patients newly diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) were identified using the Optum database and classified into the following cohorts: * First treatment cohort: Patients newly diagnosed with CML who received first treatment with a TKI. * Second treatment cohort: Patients from first treatment cohort with a subsequent line of therapy (i.e., second treatment) with a TKI. The observation period spanned from the start of data availability (i.e., 01 January 2007) to the earliest of end of data (i.e., 30 June 2022), end of continuous health plan enrollment, or death (if available). The index date was defined as the first treatment initiation for the first treatment TKI cohort and as the second treatment initiation for the second treatment TKI cohort. The baseline period consisted of the 6 months prior to the index date. The follow-up period started on the index date and ended at the earliest of end of observation period or hematopoietic stem cell transplantation (HSCT).
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,043 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2023-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06692803
The ClinicalTrials.gov registry entry for NCT06692803 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,043 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 152-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (1244% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT06692803 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06692803 about?
NCT06692803 is a clinical study titled "Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy". This was a retrospective, non-interventional, observational cohort study using Optum's de-identified Clinformatics® Data Mart Database. Adult patients newly diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) were identified using the Optum database and class...
What is the current status of trial NCT06692803?
This trial is currently completed. The enrollment target is 2,043 participants. The study started on 2023-05-23. Estimated completion is 2023-11-30.
What conditions does trial NCT06692803 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
Who is sponsoring clinical trial NCT06692803?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692803 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Study of Olverembatinib (HQP1351) in Patients With CP-CML
RECRUITING · Phase 3
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.